Clinical Trials › NCT05811416
Active, Not Recruiting
A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Sponsored by Bristol-Myers Squibb
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 200
Target enrollment
Jun 2023
Start date
Nov 2026
Expected completion
Conditions studied
Relapsing-remitting Multiple Sclerosis (RRMS)
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
